# Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

> **NCT07064759** · PHASE3 · RECRUITING · sponsor: **4D Molecular Therapeutics** · enrollment: 480 (estimated)

## Conditions studied

- Neovascular Age-Related Macular Degeneration (nAMD)

## Interventions

- **BIOLOGICAL:** 4D-150 IVT (3E10 vg/eye)
- **BIOLOGICAL:** EYLEA® (aflibercept) Injection 2 mg (0.05mL)

## Key facts

- **NCT ID:** NCT07064759
- **Lead sponsor:** 4D Molecular Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-22
- **Primary completion:** 2028-11
- **Final completion:** 2029-02
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07064759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07064759, "Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07064759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*